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Cerebral cortexMissense mutations in CACNA1A, the gene that encodes the pore-forming α1 subunit of human voltage-gated
CaV2.1 (P/Q-type) calcium channels, cause a rare form of migraine with aura (familial hemiplegic migraine
type 1: FHM1). Migraine is a common disabling brain disorder whose key manifestations are recurrent
attacks of unilateral headache that may be preceded by transient neurological aura symptoms. This review,
ﬁrst, brieﬂy summarizes current understanding of the pathophysiological mechanisms that are believed to
underlie migraine headache, migraine aura and the onset of a migraine attack, and brieﬂy describes the local-
ization and function of neuronal CaV2.1 channels in the brain regions that have been implicated in migraine
pathogenesis. Then, the review describes and discusses i) the functional consequences of FHM1mutations on
the biophysical properties of recombinant human CaV2.1 channels and native CaV2.1 channels in neurons of
knockin mouse models carrying the mild R192Q or severe S218L mutations in the orthologous gene, and
ii) the functional consequences of these mutations on neurophysiological processes in the cerebral cortex
and trigeminovascular system thought to be involved in the pathophysiology of migraine, and the insights
into migraine mechanisms obtained from the functional analysis of these processes in FHM1 knockin mice.
This article is part of a Special Issue entitled: Calcium channels.
© 2012 Elsevier B.V. All rights reserved.Contents1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1655
2. Migraine pathophysiological mechanisms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1657
3. Neuronal CaV2.1 channels: localization and function in regions involved in migraine pathogenesis . . . . . . . . . . . . . . . . . . . . . 1658
3.1. Cerebral cortex . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1658
3.2. Trigeminovascular system . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1658
3.3. Cerebellum . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1658
4. Effect of FHM1 mutations on the biophysical properties and modulation of CaV2.1 channels . . . . . . . . . . . . . . . . . . . . . . . . 1658
4.1. Biophysical properties of mutant CaV2.1 channels . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1658
4.2. Modulation of mutant CaV2.1 channels . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1659
5. Effect of FHM1 mutations on neurophysiological processes in the cerebral cortex . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1659
5.1. Cortical excitatory and inhibitory synaptic transmission . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1659
5.2. Cortical spreading depression . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1660
6. Effect of FHM1 mutations on trigeminal ganglion neurons and meningeal nociceptors . . . . . . . . . . . . . . . . . . . . . . . . . . . 1661
7. Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1662
Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1663
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1663m channels.
le G. Colombo 3, 35121 Padova,
rights reserved.1. Introduction
Migraine is a remarkably common episodic neurological disorder
(e.g. it affects 17% of females and8% ofmales in the European population
[1]) characterized by recurrent attacks of typically throbbing and unilat-
eral, often severe, headache with certain associated features such as
1656 D. Pietrobon / Biochimica et Biophysica Acta 1828 (2013) 1655–1665nausea, phonophobia and/or photophobia; in a third of patients the head-
ache is preceded by transient neurological symptoms, that are most
frequently visual, but may involve other senses (migraine with aura:
MA) [2]. Migraine is a complex genetic disorder, with heritability esti-
mates as high as 50% and a likely polygenic multifactorial inheritance
[3]. Although recent genome-wide association studies have identiﬁed
a few risk factors for migraine [4–6], most of our current molecular un-
derstanding comes from studies of familial hemiplegicmigraine (FHM),
a rare monogenic autosomal dominant form of MA [3,7,8].
Three FHM causative genes have been identiﬁed, all encoding ion
channels or transporters [9–11]. FHM type 1 (FHM1) is caused by mis-
sense mutations in CACNA1A (chromosome 19p13), that encodes the
pore-forming α1 subunit of human voltage-gated CaV2.1 (P/Q-type)
calcium channels [9].
CaV2.1 channels are located in presynaptic terminals and somato-
dendritic membranes throughout the mammalian brain and spinal cord
[12], and play a prominent role in initiating action potential (AP)-evoked
neurotransmitter release at central nervous system synapses [13]. At
many central synapses P/Q-, N- and R-type Ca2+ (Ca) channels cooperate
in controlling neurotransmitter release, but P/Q-type channels have a
dominant role, partly because of amore efﬁcient coupling to the exocytot-
ic machinery [14–16]. Moreover, at many central synapses, there is a
developmental change in the Ca channel types mediating synaptic trans-
mission, whereby the relative contribution of P/Q-type channels to
release increaseswithpostnatal age, until release becomes exclusively de-
pendent on P/Q-type channels [17]. Among the presynaptic Ca channels,
CaV2.1 channels are unique also in their capacity for interacting with and
being modulated in a complex manner by a number of Ca-binding pro-
teins ([18] for review and references). As a result, CaV2.1 channels may
exhibit both Ca-dependent inactivation and Ca-dependent facilitation.
Ca-dependent regulation of presynaptic CaV2.1 channels may play a cru-
cial role in short-term synaptic plasticity during trains of action potentials
[19–21]. Differential expression of the different Ca-dependent regulatory
proteins and/or of different CaV2.1 splice variantsmay provide ameans of
neuron-type speciﬁc regulation of presynaptic P/Q channels and short-
term plasticity. The somatodendritic localization of CaV2.1 channels
points to additional postsynaptic roles, e.g. in neural excitability [22,23],
gene expression [24] and cell survival [25].
The FHM1 mutations produce substitutions of conserved aminoacids
in important functional regions of the CaV2.1 channel including the pore
lining and the voltage sensors (see [8,26] for recent reviews and
references). A few additional CACNA1Amissensemutations affecting
conserved aminoacids have been found in patients with sporadicV581M
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Fig. 1. Location of FHM1 (red) and SHM1 (blue) mutations in the secondary structure of the
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those whose effects have been studied also in transfected neurons from CaV2.1−/− mice exhemiplegic migraine (SHM1) with similar symptoms as FHM but whose
parents did not carry the mutation (e.g. [27]). Fig. 1 shows the location
of FHM1 (and a few SHM1) mutations in the secondary structure of the
CaV2.1α1 subunit, consisting of four repeated domains (I–IV) each of
which contains six transmembrane segments (S1–S6) and a pore loop
connecting S5 and S6 [28].
FHM1 can be considered a model for the common forms of migraine
because, apart from the motor weakness or hemiparesis during aura
(and the possibly longer aura duration), typical FHM attacks resemble
MA attacks [2] and both types of attacks may alternate in patients and
co-occur within families [3,7,8]. However, several FHM1 families show
permanent cerebellar symptoms (such as slowly progressive cerebellar
ataxia and/or nystagmus with cerebellar atrophy in some cases), that
are usually not observed in common migraines. Pure FHM1 and FHM1
with cerebellar symptoms are usually associated with different muta-
tions. Moreover, in addition to typical attacks, patients of some FHM1
families can have atypical severe attacks with signs of diffuse encepha-
lopathy, impairment of consciousness (coma) or confusion, fever,
prolonged hemiplegia lasting several days, and in a few cases seizures;
this severe clinical phenotype is shown by most SHM1 patients. [8,29].
The incomplete penetrance of FHM1 (67% in a population-based sample
of FHM families: [30]) and the symptom variability among subjects with
the same mutation suggests that other genetic or environmental factors
also inﬂuence the phenotype [8,29].
Two different FHM1 knockin mouse models have been generated by
introducing the humanR192Q and S218Lmutations into the orthologous
cacna1a CaV2.1 channel gene [31,32].WhereasmutationR192Q causes in
humans pure FHM, mutation S218L causes a particularly dramatic clini-
cal syndrome, that may consist of, in addition to attacks of hemiplegic
migraine, slowly progressive cerebellar ataxia and atrophy, epileptic
seizures, coma or profound stupor and severe, sometimes fatal, cerebral
edema which can be triggered by only a trivial head trauma [32,33].
Whereas homozygous R192Q and heterozygous S218L knockin mice
did not exhibit an overt phenotype, homozygous S218L mice exhibited
mild permanent cerebellar ataxia, spontaneous attacks of hemiparesis
and/or (sometimes fatal) generalized seizures, and brain edema after
only a mild head impact, thus modeling the main features of the severe
S218L clinical syndrome [31,32].
Here, I ﬁrst brieﬂy summarize current knowledge of the main patho-
physiologicalmechanisms that are believed to underliemigraine and de-
scribe the localization and function of neuronal CaV2.1 channels in the
brain regions that have been implicated in migraine pathogenesis.
Then, I review current knowledge of i) the functional consequences of7Q
0Y
C
18 C1535S
19 R1668W
20 K1671R
17 F1507S
21 L1682P6E
0Q
16 V1457L
22
23
24
25
W1684R
V1696I
I1710T
I1811L
COOH
    2   3   4   5           6 1    2   3   4   5           6
+
+
+
+
+
+
12
11
14
16
18
15
23
21
19
22
24
25
13
17 20
CaV2.1α1 subunit. Given the difﬁculty in distinguishing a pathogenic mutation from a
trols or parents and affecting conserved aminoacids are shown. Also not shown are: the
onozygotic twin pair with complex symptoms that clinically overlaps with both alter-
ound in individuals with a strong family history although other family members were
as V581M [145]. Reference sequence Genbank Acc. No. X99897. The mutations written
ls have been studied in heterologous expression systems; the mutations underlined are
pressing human CaV2.1α1 subunits.
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CaV2.1 channels in transfected cells and native CaV2.1 channels in neu-
rons of the FHM1 mouse models; and ii) the functional consequences of
these mutations on neurophysiological processes in the cerebral cortex
and trigeminovascular system of FHM1 knockin mice.
2. Migraine pathophysiological mechanisms
It is generally believed that:
i) the headache phase of migraine begins with the activation and
sensitization of trigeminal sensory afferents that innervate cranial
tissues, in particular the meninges and their large blood vessels;
this then leads to sequential activation (and, in most patients,
sensitization) of second and third order trigeminovascular neu-
rons (in the trigeminal nucleus caudalis and speciﬁc thalamic
nuclei, respectively), which in turn activate different areas of the
brainstem and forebrain resulting in pain and other symptoms of
migraine; the bidirectional signaling between many of these
areas contributes to the complexity of the symptoms (see [34–
36] for recent reviews and references; see also [37] for an alterna-
tive view thatmigraine headache arises from a dysfunctionwithin
the subcortical brainstem and diencephalic nuclei that modulate
trigeminal nociceptive inputs).
ii) cortical spreading depression (CSD) is the phenomenon underly-
ingmigraine aura; CSD can be induced in animals by focal stimu-
lation of the cerebral cortex and consists of a slowly propagating
(2–6 mm/min) wave of strong neuronal and glial depolarisation
(see [38–41] for reviews and references). Although the mecha-
nisms of initiation and propagation of CSD remain unclear, it is
believed that the initiation of the positive feedback cycle that
ignites CSD and almost zeroes the neuronal membrane potential
depends on the local increase of the extracellular concentration
of K+ ions above a critical value and on the activation of a net
inward current at the pyramidal cell dendrites [42].
iii) most migraine attacks start in the brain, as suggested by the pre-
monitory symptoms (such as difﬁculty with speech and reading,
increased emotionality, sensory hypersensitivity), that in many
patients are highly predictive of the attack although occurring
up to 12 h before it, and as suggested also by the nature of some
typical migraine triggers such as stress, sleep deprivation, over-
sleeping, hunger, prolonged sensory stimulation; moreover, psy-
chophysical and neurophysiological studies have provided clear
evidence that in the period between attacks migraineurs show
hypersensitivity to sensory stimuli and abnormal processing of
sensory information (see [36,43,44] for reviews and references).
The mechanisms of the primary brain dysfunction(s) leading to the
onset of a migraine attack, to CSD susceptibility and to episodic activa-
tion of the trigeminovascular pain pathway remain largely unknown
and themajor open issue in the neurobiology of migraine. Other impor-
tant open questions concern the mechanisms underlying the sustained
activation and sensitization of the trigeminovascular system resulting
in the typical long-lasting throbbing headache, and themechanisms un-
derlying increased migraine frequency and the “transformation” from
episodic to chronic migraine, e.g.as a consequence of the frequent use
of analgesic medications [2].
While there is growing evidence that vasodilation of meningeal and/
or extracranial arteries is neither necessary nor sufﬁcient to cause mi-
graine pain in most patients ([45] and references therein), a large body
of indirect evidence supports the idea that a sterile meningeal inﬂamma-
tion is a keymechanism thatmay activate and sensitize perivascularmen-
ingeal afferents and lead to migraine pain (reviewed in [35,36,46,47]).
Whilemost dural afferents can be activated and sensitized by an inﬂam-
matory soup and are capsaicin-sensitive, thus exhibiting properties
characteristic of nociceptors in other tissues [35,48–54], the endoge-
nous processes that promote meningeal inﬂammation and peripheralsensitization during migraine attacks remain unclear. Although direct
evidence is lacking, many investigators consider the neurogenic inﬂam-
mation produced by release of vasoactive proinﬂammatory neuropep-
tides (including calcitonin gene-related peptide, CGRP, substance P,
neurokinin A) following activation of peptidergic meningeal nociceptors
(by CSDor other different primarymechanisms, see below) as the endog-
enous inﬂammatory process that sustains the activation and causes the
long-lasting sensitization of meningeal nociceptors in many migraine at-
tacks; alternatively, it has been suggested that mediators released by the
CSD wave may lead to sensitization and ensuing activation of meningeal
nociceptors (cf [36] for recent review and references). Measurements of
CGRP levels into the external and internal jugular venous blood have pro-
vided evidence that CGRP is released during migraine attacks (reviewed
in [55–57]).
Several ﬁndings support a pivotal role of CGRP in migraine, including
i) the effectiveness of CGRP receptor antagonists in migraine treatment
and ii) the induction of a delayedmigraine-like headache by intravenous
CGRP administration in a large fraction of migraine patients but not in
control, suggesting that most migraineurs are hypersensitive to CGRP-
mediated modulation of nociceptive pathways ([55–57] and references
therein). However, the mechanisms underlying this hypersensitivity,
the mechanisms of action of CGRP during a migraine attack and the
exact sites of action of CGRP receptor antagonists remainunclear and con-
troversial. The localization of CGRP receptors in the trigeminovascular
system points to multiple possible mechanisms at both peripheral and
central sites [58].
Increasing evidence fromanimal studies support the idea that CSD can
activate trigeminal nociception and thus trigger the headache mecha-
nisms [36]. A direct nociceptive effect of CSD has been demonstrated by
theﬁnding that a single CSD can lead to a long-lasting increase in ongoing
activity of dural nociceptors and central second order trigeminovascular
neurons [59,60], and evokes alterations in the meninges and brainstem
consistent with the development of pain [61]. The idea that CSD is nox-
ious and may trigger headache is indirectly supported by the ﬁnding
that the electrical stimulation threshold for induction of CSD in the rat
cortex increases after chronic treatment with ﬁve differentmigraine pro-
phylactic drugs, that are effective in reducing the frequency of migraine
attacks (both with and without aura) [62]. Moreover further support to
the view of CSD as a key migraine trigger has been provided by the anal-
ysis of experimental CSD in FHM knockin mouse models, that revealed a
lower electrical stimulation threshold for CSD induction and a higher
velocity of CSD propagation in both FHM1 and FHM2 knockin mice
[31,32,63,64] (see Section 5.). However, despite the strong support pro-
vided by animal studies, the idea that CSD may initiate the headache
mechanisms in migraine is not generally accepted, mainly because it
seems unable to explain some clinical observations, in particular the
lack of a ﬁxed relationship between aura and headache (reviewed in
[36,39,65]).
The analysis of interictal cortical excitability using psychophysical,
electrophysiological and brain imaging methods has produced contra-
dictory ﬁndings and interpretations regarding the mechanisms under-
lying the abnormal processing of sensory information in migraineurs
(see [36,39,43,44] for reviews and references). Interestingly, recent trans-
cranial magnetic stimulation studies in MA patients point to deﬁcient
regulatory mechanisms of cortical excitability and consequent reduced
ability to dynamically maintain the cortical excitatory–inhibitory balance
and to prevent excessive increases in cortical excitation, rather than
merely hypo- or hyperexcitability, as the mechanisms underlying abnor-
mal sensory processing [66–68]. The molecular and cellular mechanisms
underlying the abnormal regulation of cortical function and the increased
susceptibility to CSD inmigraine remain largely unknown. As discussed in
Section 5, the functional analysis of FHMknockinmousemodels supports
the view of migraine as a disorder of brain excitability characterized by
deﬁcient regulation of the cortical excitatory–inhibitory balance, and
gives insights into the possible underlyingmolecular and cellular mecha-
nisms and their relationship to CSD susceptibility.
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CaV2.1 channels are expressed in all brain regions that have been im-
plicated in the pathogenesis of migraine and/or migraine pain, including
the cerebral cortex, the trigeminal ganglia, and brainstemnuclei involved
in the central control of nociception; their expression is particularly high
in the cerebellum, a feature that explains the cerebellar symptoms caused
by several FHM1 mutations ([39] and references therein).
3.1. Cerebral cortex
In the cerebral cortex, excitatory synaptic transmission at pyramidal
cell synapses in different cortical areas depends predominantly on
P/Q-type Ca channels [17,69–73] with a notable exception at synapses
between layer 5 pyramidal cells and burst-ﬁring bipolar interneurons
of the motor cortex [70]. Activation of the cortex following thalamic
stimulation in thalamocortical slices was completely inhibited by
blocking P/Q Ca channels [74]. Relatively little is known on the Ca chan-
nels initiating inhibitory neurotransmission in the cortex, since the Ca
channel pharmacology has been investigated only at the synapses be-
tween fast-spiking (FS) interneurons and pyramidal cells; neurotrans-
mission was found to be exclusively dependent on P/Q-type channels
in many cortical areas [72,73,75], but again with the exception of layer
5 of the motor cortex, where it was exclusively dependent on N-type
[70]. An impairment of feedforward inhibition from thalamus to layer
4, probably due to impaired synaptic transmission at FS-pyramidal cell
synapses, was revealed in totteringmice carrying a loss-of-functionmu-
tation in CaV2.1 [76].
P/Q-type Ca channels account for about one third of the Ca current in
dissociated cortical pyramidal neurons [77,78] andmediate about 40% of
theAP-evoked Ca inﬂux in dendritic spines and shaft of layer 2/3 cortical
pyramidal neurons [69]; they contribute to the regulation of the intrinsic
ﬁring of the same neurons via activation of different Ca-dependent K+
channels [22]. In thalamocortical neurons, P/Q channels are essential
for the generation of high-frequency subthreshold gamma-band oscilla-
tions, that are characteristic of the aroused attentive state and consid-
ered a functional prerequisite to cognitive states [74]. Null CaV2.1−/−
mice and the majority of the spontaneous mutants harboring loss-
of-function mutations in CaV2.1 show absence seizures (reviewed in
[26]).
3.2. Trigeminovascular system
In the trigeminovascular system, P/Q-type Ca channels account for a
large proportion of the Ca current of dissociated trigeminal ganglion
(TG) neurons [51,79,80], and are involved in the control of CGRP release
from perivascular terminals of meningeal nociceptors [81,82] and of
glutamate release from TG neurons in culture [83]. P/Q channels are
also involved in controlling tonic inhibition of trigeminal nucleus
caudalis neurons with input from the dura [84], and in descending in-
hibitory and facilitatory pathways that regulate trigeminal and spinal
pain transmission [85,86]. A possible role of P/Q channels in central sen-
sitization of the trigeminovascular system is suggested by pharmaco-
logical evidence in the spinal cord [87], and by the ﬁnding of reduced
responses to inﬂammatory and neuropathic pain in CaV2.1−/+ mice,
carrying a genetic ablation of the CaV2.1α1 subunit that reduces to
half the CaV2.1 channels [88]; it is noteworthy that age-matched
CaV2.1−/+ mice do not show any motor or other neurological deﬁcit,
despite the particularly high expression of CaV2.1 channels in the cere-
bellum and their key role in cerebellar synaptic transmission and neu-
ron excitability (see below). The analysis of the pain responses in
CaV2.1−/− null mice revealed a complex role of CaV2.1 channels in
pain: a pronociceptive role in inﬂammatory and neuropathic pain but
an antinociceptive role in response to acute non-injurious noxious ther-
mal stimuli [88]; this complex picture likely reﬂects the prominent roleof P/Q channels in controlling release of both excitatory and inhibitory
neurotransmitters and their wide distribution in different regions in-
volved in pain.
3.3. Cerebellum
In the cerebellum, P/Q-type Ca channels account for most of the Ca
current in Purkinje cells and a large fraction of the Ca current in granule
cells [77,89,90], and play a dominant role in initiating both excitatory and
inhibitory neurotransmission [14,17,91–93]. P/Q-type Ca channels also
play a key role in themaintenance of the highly regular, spontaneous in-
trinsic pacemaking of Purkinje cells, because they are speciﬁcally coupled
to the Ca-activated K+ channels that control the afterhyperpolarization
amplitude and the frequency and regularity of tonic ﬁring [23]. More-
over, CaV2.1 channels in Purkinje cells are essential for competitive syn-
aptic wiring and cell survival [94–96]. Deletion of the CaV2.1α1 mouse
gene leads to severe cerebellar ataxia and dystonia together with selec-
tive progressive cerebellar degeneration [25,97,98]. Different mouse
strains with spontaneous CaV2.1α1 mutations all suffer from ataxia and
exhibit reduced P/Q-type current in Purkinje cells (reviewed in [99]).
In humans, mutations in the CACNA1A gene cause, in addition to
FHM1, a few autosomal dominant neurological disorders characterized
by cerebellar dysfunction, such as episodic ataxia type 2 (EA2, that may
be associated with absence epilepsy in a few cases) and spinocerebellar
ataxia type 6 [9,100,101]. EA2 mutations lead to loss-of-function of
recombinant humanCaV2.1 channels in heterologous expression systems,
whereas SCA6pathogenesis likely involves a toxic gain-of-functionmech-
anism associated with accumulation of themutant protein similar to that
of other polyglutamine diseases (reviewed in [99]).
4. Effect of FHM1 mutations on the biophysical properties and
modulation of CaV2.1 channels
The effect on the biophysical properties of CaV2.1 channels of 13 FHM1
mutations (in green in Fig. 1) has been investigated in heterologous ex-
pression systems expressing recombinant (human in most studies)
CaV2.1 channels [102–114] (our unpublished observations; cf also
[26,115] for recent reviews); ﬁve of these mutations (underlined in
Fig. 1) have also been investigated in transfected neurons from
CaV2.1−/− mice expressing human CaV2.1α1 subunits [80,102,107,116,
117]. Moreover, the effect of mutations R192Q and S218L on neuronal
CaV2.1 channels has also been analyzed in different neurons of FHM1
knockin mice, in which the mutant Ca channels are expressed at the
endogenous level [31,32,51,73,113,118].
4.1. Biophysical properties of mutant CaV2.1 channels
The analysis of the single channel properties of mutant recombinant
human CaV2.1 channels and of the P/Q-type Ca current in neurons of
FHM1 knockin mice revealed that the FHM1 mutations produce gain-
of-function of CaV2.1 channels, mainly due to increased channel open
probability and channel activation at lower voltages. In fact, the eight
different human FHM1mutants, that were analyzed at the single chan-
nel level, all showed an increased channel open probability and single
channel Ca inﬂux (asmeasured by the product of single channel current
and open probability) in a wide range of depolarizations, mainly due to
a shift to lower voltages of channel activation [102,106,107,115] (our
unpublished observations). Congruently, the analysis of the P/Q-type
calcium current in different neurons (including cortical and TG neu-
rons) of FHM1 knockin mice revealed gain-of function of the CaV2.1
current in a wide range of relatively mild depolarizations, reﬂecting
shifted activation of mutant CaV2.1 channels to more negative voltages
[31,32,51,73,118]. P/Q current densities were similar in knockin and
wild-type (WT) neurons at higher voltages (that elicit maximal CaV2.1
channel open probability), indicating similar densities of functional
CaV2.1 channels [31,32,51,73]. The shift to lower voltages of CaV2.1
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current were about twice as large in homozygous compared to heterozy-
gous knockinmice, revealing an allele-dosage effect consistentwith dom-
inance of the mutation in FHM1 patients [32]. In agreement with the
lower threshold of activation of human S218L CaV2.1 channels compared
to that of humanR192QCaV2.1 channels [107], the gain-of-function of the
P/Q Ca current at low voltages was larger in cerebellar granule cells of
S218L than R192Q knockin mice [31,32]. Two photon microscopy in
cerebellar slices of S218L knockin mice revealed increased AP-evoked
Ca transients in individual synaptic terminals of cerebellar granule cells,
a ﬁnding consistent with increased open probability ofmutant presynap-
tic CaV2.1 channels [113], that may be due to shifted activation to lower
voltages, as shown for the somatic channels [32], and/or to basal Ca-
dependent facilitation of mutant channels as suggested by the authors
[113] (cf below).
In contrastwith the good agreement between the gain-of-function of
the neuronal P/Q current in R192Q and S218L knockin mice and the
gain-of-function of the single channel inﬂux through recombinant
human R192Q and S218L CaV2.1 channels, the maximal whole-cell P/Q
Ca current density in transfected neurons expressing the same human
R192Q and S218L CaV2.1 channels was found to be lower than that in
neurons expressing the humanWT channel; at lowvoltages, P/Q current
densities were similar to, or in the case of the S218L mutation larger
than WT because of the negatively shifted activation of the FHM1
mutants [102,107,116,117] (cf Fig. 3 in [26]). As discussed in [26] (cf
also [107]), the decreased P/Q current density at high voltages (where
the open probability of CaV2.1 channels is maximal and similar for mu-
tant and WT channels) in transfected neurons expressing the mutant
channels must reﬂect a decreased density of functional channels in the
membrane; likely, the decreased density of functionalmutant channels
is a consequence of overexpression since it is not observed in neurons
of knockin mice expressing the mutant channels at the endogenous
level. On the other hand, the electrophysiological analysis in neurons
of knockin mice and in transfected cells and/or neurons led to similar
conclusions regarding the effect of the FHM1 mutations on the gating
properties of the CaV2.1 channel. As a matter of fact, the analysis of the
gating properties of 13 different FHM1 mutants in transfected cells
usingwhole-cell current recordings revealed consistent (and signiﬁcant
for themajority of themutations analyzed so far) shifts to lower voltages
of activation of themutant channels [102–108,110–112,114]. Moreover,
these studies have shown that, besides the consistent effect on channel
activation, the FHM1 mutations may also alter the inactivation proper-
ties of CaV2.1 channels; the effects were different depending on themu-
tation and e.g. resulted in increased, decreased or unaltered inactivation
during train of pulses, depending on the mutation.
For certain mutations, the speciﬁc alterations of channel gating,
including the magnitude (or even the presence) of the shift to lower
voltages of channel activation, depended on the CaV2.1α1 splice variant
and the type of coexpressed β subunit [103,112]. The use of different
CaV2.1 splice variants and/or β subunits might explain some discrepan-
cies existing in the literature regarding the functional effects of some
FHM1 mutations in transfected cells: e.g. the T666M mutation was
shown to produce a negative shift of CaV2.1 activation in [102,105]; in
contrast, a lack of effect on activation gating was reported in [80,109].
Moreover, the expression of speciﬁc CaV2.1 splice variants and/or auxil-
iary subunits in different neuronsmight underlie the recent ﬁnding of a
differential effect of the R192Q mutation on activation gating of native
P/Q-type Ca channels in different TG neurons of knockin mice [51]. In
small capsaicin-insensitive TG neurons characterized by expression of
T-type Ca currents (CI-T neurons) from R192Q knockin mice there
was a larger P/Q-type Ca current density following mild depolariza-
tions and a larger AP-evoked P/Q calcium current when compared
to CI-T neurons fromWTmice. In striking contrast, the P/Q-type cur-
rent density, voltage dependence and kinetics were not altered by
the FHM1 mutation in small capsaicin-sensitive neurons of R192Q
knockin mice [51].While in cortical pyramidal cells of R192Q KI mice the shift to
lower voltages of CaV2.1 channel activation resulted in increased
AP-evoked Ca current, a similar shift of mutant R192Q channels at
the Calyx of Held synaptic terminals did not alter the AP-evoked Ca
current [118]. The different durations of the AP in pyramidal cells
and Calyx (1.8 vs 0.44 ms AP half width) may largely explain the dif-
ferential effects of the FHM1 mutation on the AP-evoked Ca current;
in fact, the AP-evoked Ca current became larger in knockin compared
to WT Calyx terminals when the longer duration pyramidal cell AP
was used as depolarizing stimulus [118].
The ﬁndings of [51] and [118] have important general implications
for familial migraine mechanisms, in that neuron subtype-speciﬁc
(and/or subcellular compartment-speciﬁc) alterations of CaV2.1 chan-
nels and/or AP-evoked Ca inﬂux may help to explain why a mutation
in a calcium channel that is widely expressed in the nervous system
[12] produces the speciﬁc neuronal dysfunctions leading to migraine
(see next section).
4.2. Modulation of mutant CaV2.1 channels
The investigation of the effect ofﬁve different FHM1mutations on the
modulation of recombinant human CaV2.1 channels by G proteins, re-
vealed a consistent reduction of G-protein mediated channel inhibition
[108,110,111,114], an effect that may lead to further gain-of-function
of Ca inﬂux throughmutant channels during neuromodulation. Although
there is some controversy regarding the mechanism of the reduced
G-protein modulation of mutant channels, most studies are consistent
with the conclusion that FHM1 mutations increase the rate of dissocia-
tion of Gβγ subunits fromFHM1mutant channels [110,111,114]without
altering the rate of association of the Gβγ subunits [108,110,111], thus
promoting channel deinhibition. The only study that investigated
voltage-dependent G-protein modulation using physiological-like stim-
uli revealed a reduced facilitation of the Ca current carried by mutant
channels after a train of short depolarizing pulses in cells overexpressing
Gβγ subunits and a reduced Gβγ-mediated inhibition of the Ca current
evoked by AP-like stimuli; the reduction of G-protein modulation was
dependent on the duration of the AP, being larger with APs of longer du-
ration, in agreement with an increased rate of dissociation of Gβγ sub-
units resulting in channel deinhibition that becomes more evident with
longer stimuli [111].
Besides G proteinmodulation, the FHM1mutationsmay also reduce
Ca-dependent facilitation (CDF) of CaV2.1 channels. CDF of recombinant
CaV2.1 channelswas largely reduced by the R192Qmutation and almost
eliminated by the S218Lmutation [113], suggesting that the increase in
the open probability of mutant channels (larger for S218L than R192Q:
[107]) partially or completely occludes further facilitation. CDF of native
CaV2.1 channels in Purkinje cells of S218L knockin mice was also re-
duced [113]. In contrast, CDF of native CaV2.1 channels in both Purkinje
cells [113] and Calyx of Held synaptic terminals [118] of R192Q knockin
mice was not signiﬁcantly affected, suggesting that also the effect of
FHM1 mutations on CDF likely depends on the speciﬁc CaV2.1 variant
expressed in a given neuron or neuronal subcompartment.
5. Effect of FHM1 mutations on neurophysiological processes in
the cerebral cortex
5.1. Cortical excitatory and inhibitory synaptic transmission
The analysis of cortical excitatory synaptic transmission in neuronal
microcultures and in brain slices fromR192Q knockinmice revealed en-
hanced excitatory neurotransmission, due to enhanced action-potential
evoked Ca inﬂux through mutant presynaptic P/Q Ca channels and
enhanced probability of glutamate release at cortical pyramidal cell
synapses [73]. Short-term synaptic depression during trains of action
potentials was also enhanced. Neither amplitude nor frequency of minia-
ture excitatory postsynaptic currentswere altered, indicating the absence
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pyramidal cells [73]. Although indirect, evidence for gain-of-function of
excitatory neurotransmission has also been obtained at parallel ﬁbers—
Purkinje cell synapses in cerebellar slices of S218L knockin mice [113]
and at excitatory synapses onto dorsal suprachiamastic nucleus neurons
of R192Q knockin mice [119].
In striking contrast with the enhanced glutamatergic transmission,
paired recordings of fast spiking (FS) inhibitory interneurons and
layer 2/3 pyramidal cells in acute cortical slices revealed that the inhib-
itory GABAergic transmission at FS synapses was not altered in R192Q
knockin mice, despite being initiated by P/Q Ca channels [73]. The
main explanation for the unaltered GABA release at FS interneuron syn-
apses of juvenile knockin mice appears to be the speciﬁc expression in
FS interneurons of a CaV2.1 subtype whose gating properties are little
affected by the mutation (Vecchia, Tottene and Pietrobon, unpublished
observations).
The demonstration that FHM1 mutations may differently affect syn-
aptic transmission and short-term synaptic plasticity at different cortical
synapses implies that, very likely, the neuronal circuits that dynamically
adjust the balance between excitation and inhibition during cortical
activity are altered in FHM1 [73]. Functional alterations in these cir-
cuits are expected to lead to dysfunctional regulation of the cortical
excitatory–inhibitory balance and hence to abnormal processing of sen-
sory information [120,121].
5.2. Cortical spreading depression
The investigation of experimental CSD, elicited either by electrical
stimulation of the cortex in vivo or high KCl in cortical slices, revealed a
lower threshold for CSD induction and an increased velocity of CSDprop-
agation in R192Q and S218L knockin compared to WT mice [31,32,73].
Moreover, a single CSD, elicited by brief epidural application of high
KCl, produced more severe and prolonged motor deﬁcits (including
hemiplegia) in FHM1 knockin mice, and, in contrast with WT mice,
CSD readily propagated into the striatum [64,122]. Themuch higher pro-
pensity of CSD to propagate to the striatum in FHM1mutants compared
to WT mice may explain their motor deﬁcits and the hemiplegia typical
of FHM1 aura. In agreement with the higher incidence of migraine in
females, the velocity of propagation and the frequency of CSDs, elicited
by continuous epidural high KCl application, were larger in females
than in males of both mutant strains; the sex difference was abrogated
by ovariectomy and enhanced by orchiectomy, suggesting that female
and male gonadal hormones exert reciprocal effects on CSD susceptibil-
ity [64,123]. The strength of CSD facilitation as well as the severity of the
post-CSD neurological motor deﬁcits and the propensity of CSD to prop-
agate into subcortical structures in R192Q and S218L knockin mice were
all in good correlation with the strength of the gain-of-function of the
CaV2.1 channel and the severity of the clinical phenotype produced by
the two FHM1 mutations [31–33,64,107,122]. Propagation of CSD to
the hippocampus and thalamus and repetitive CSD events following a
single CSD-inducing stimulus were observed only in S218L mutants
[32,122]. These unique CSD featuresmight account for the severe attacks
with seizures, coma and cerebral edema typical of patients with the
S218L mutation.
Recently, it has been shown that the frequency of periinfarct ische-
mic depolarizations during acute experimental stroke and the critical
tissue perfusion level below which infarction ensues are both larger in
S218L knockin compared to WT mice [124]. These ﬁndings point to in-
creased vulnerability to ischemic stroke as a consequence of increased
susceptibility to ischemic depolarizations akin to CSD in these FHM1
mutants. Similar mechanisms might underlie the recurrent ischemic
strokes after minor head trauma recently reported in a young girl with
severe FHM carrying a de novo mutation (R1350Q) in the CaV2.1 chan-
nel gene [125]. Although the effects of this mutation on CaV2.1 channel
function have not been studied, it is homologous to the R1252Q muta-
tion in the spontaneous cacna1a mouse mutant Tg-5J mice, that wasreported to shift to lower voltages the activation of recombinant (and
native cerebellar) CaV2.1 channels [126].
It has been shown that the gain-of-function of glutamate release at
synapses onto cortical pyramidal cells can explain the facilitation of ex-
perimental CSD in FHM1 knockin mice [73]. In fact, the facilitation of
CSD in acute cortical slices of R192Q knockinmice was completely elim-
inated (both CSD threshold and velocity became similar to those in WT
slices) when glutamate release at pyramidal cell synapses was brought
back to WT values by partially inhibiting P/Q channels [73]. The data
are consistent with and support a model of CSD initiation in which
CaV2.1-dependent release of glutamate from cortical pyramidal cell syn-
apses and activation of NMDA receptors (and possibly postsynaptic
CaV2.1 channels) play a key role in the positive feedback cycle that
ignites CSD [73,127]. This model and in general the speciﬁc requirement
of CaV2.1 channels in the initiation and propagation of CSD (induced in
normally metabolizing tissue by electrical stimulation or brief pulses of
high K+) are further supported by the ﬁndings that i) in the spontane-
ous mouse mutants leaner and tottering, that carry loss-of-function mu-
tations in cacna1a [26], the in vivo electrical threshold for CSD initiation
was higher and the CSD velocity smaller than in WT mice [128] and ii)
after blockade of either the P/Q-type Ca channels or the NMDA recep-
tors, CSD could not be induced in cortical slices of WT mice (with K+
pulses up to 30 times longer than the threshold pulses triggering CSD
in control); in contrast, blockade of N- or R-type Ca channels had only
a small inhibitory effect on CSD threshold and velocity of propagation
[129].
As a whole, the studies of experimental CSD in FHM1 knockin mice
strengthen the view of CSD as a key player in the pathogenesis of mi-
graine. Inmigraineurs, CSD is not induced by experimental depolarizing
stimuli, but arises “spontaneously” in response to speciﬁc triggers, that
somehow create in the cortex conditions for initiation of the positive
feedback cycle that overwhelms the regulatorymechanisms controlling
cortical [K+]o and ignites CSD. Insights into how this might occur have
been provided by the differential effect of FHM1 mutations on cortical
excitatory and inhibitory synaptic transmission [73] suggesting altered
regulation of the cortical excitatory–inhibitory balance in FHM1. It has
been hypothesized that this dysregulation may in certain conditions
(e.g. in response tomigraine triggers such as intense, prolonged sensory
stimulation) lead to disruption of the excitatory–inhibitory balance and
hyperactivity of cortical circuits, mainly due to excessive recurrent exci-
tation, thatmay create the conditions for the initiation of “spontaneous”
CSDs (e.g. by increasing the extracellular [K+] above a critical value)
[36,73]. Similar mechanisms might underlie the susceptibility to CSD
in FHM2 [63].
Impairment of the cortical circuits that dynamically adjust the
excitatory–inhibitory balance during cortical activity, due to excessive
recurrent glutamatergic neurotransmission, might also underlie the
abnormal regulation of interictal cortical function in some common
migraine subtypes, for which there is indirect evidence consistent
with enhanced cortical glutamatergic neurotransmission [68,130] and
enhanced cortico-cortical or recurrent excitatory neurotransmission
[67,131–133]. Some of the susceptibility loci for MA and MO recently
identiﬁed in genome-wide association studies appear also consistent
with the idea of migraine as a disorder of glutamatergic neurotransmis-
sion and/or dysregulated brain excitatory–inhibitory balance [4–6].
Given the wide clinical and genetic heterogeneity of migraine, different
molecular and cellular mechanisms, that remain largely unknown, may
well underlie the impaired regulation of brain function and the suscep-
tibility to CSD in different migraineurs [36].
The conclusions regarding the functional consequences of FHM1mu-
tations derived from the functional analysis of R192Q and S218L knockin
mice (cf Fig. 2: gain-of function of cortical pyramidal cell CaV2.1 channels
with consequent gain-of-function of cortical glutamatergic synaptic
transmission causing facilitation of CSD) provide a coherent picture of
molecular and cellularmechanisms that may produce increased suscep-
tibility to CSD and thus explain the aura symptoms in FHM1 patients.
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that the aura phenotype is common to all FHM1 patients (cf also in the
previous section the consistent gain-of-function of single channel Ca in-
ﬂux through humanCaV2.1 channel produced by all the eight FHM1mu-
tations whose effect on single channel current was analyzed). The
opposite conclusions derived from the functional analysis of FHM1 mu-
tations (including the R192Q mutation) in transfected hippocampal
neurons overexpressing human CaV2.1α1 subunits (i.e. loss of function
of CaV2.1 channels with consequent decreased contribution of P/Q Ca
channels to glutamatergic synaptic transmission, and unaltered synaptic
strength due to compensatorymechanisms [116]) provide a picture that
seems unable to explain the increased susceptibility to CSD and the aura
phenotype of FHM1 patients. Thus, to be able to draw meaningful con-
clusions regarding the neurophysiological processes involved in the
pathogenesis of FHM1 (and probably neuronal channelopathies in gen-
eral), it seems essential to study these processes in neurons expressing
the channels at the native endogenous level.6. Effect of FHM1 mutations on trigeminal ganglion neurons and
meningeal nociceptors
Asmentioned in Section 4, the analysis of the P/Q-type Ca current in
two deﬁned subpopulations of small (capacitance≤20 pF) TG neurons
from adult R192Q knockin mice showed gain-of-function of the CaV2.1
channel in capsaicin-insensitive TG neurons expressing T-type Ca chan-
nels (CI-T neurons), but unaltered CaV2.1 channel gating properties in
capsaicin-sensitive TGneurons lacking T-type Ca channels (CS neurons)
[51]. WT CI-T and CS neurons were both characterized by APs of long
duration with typical shoulder and tonic or slowly adapting ﬁring.
While the rheobase (i.e. the minimal current injection that elicits APs)
and the frequency of APs were not affected by the FHM1 mutation,
the duration of the AP in CI-T neurons of R192Q knockin mice was
prolonged, due to a delayed repolarization and more pronounced
shoulder that correlatedwith the larger AP-evoked P/Q-type Ca current
measured in these neurons [51]. In contrast, neither the AP shape nor
any other excitability property were affected by the FHM1 mutation
in small capsaicin-sensitive neurons (in agreement with the unaltered
P/Q channel gating and unaltered AP-evoked P/Q current in these TG
neurons) [51].Single CaV2.1
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Fig. 2. Functional alterations in the cerebral cortex of a familial hemiplegic migraine type 1 (
citatory synaptic transmission at pyramidal cell (PC) synapses are increased, due to increased
open probability and activation at lower voltages of mutant compared to WT channels. In
spiking (FS) interneuron synapses are unaltered. The differential effect of the FHM1 mutatio
regulation of the cortical excitatory–inhibitory balance. Experimental cortical spreading dep
increased rate of CSD propagation and an increased propensity to propagate into subcorticMeasurements of the Ca current in small TGneurons retrogradely la-
beled from the dura revealed that a major fraction of small dural affer-
ents were CS neurons and none were CI-T neurons [51]. Several lines of
evidence indicate thatmost small capsaicin-sensitive dural afferents are
peptidergic neurons expressing CGRP [134–136] and it has been shown
that P/Q-type Ca channels contribute to control CGRP release from
capsaicin-sensitive perivascular meningeal sensory ﬁbers [81,82]. Mea-
surements of CGRP release from dura mater in ﬂuid-ﬁlled hemisected
skulls revealed that neither basal nor K+-evoked CGRP releasewere sig-
niﬁcantly different in R192Q knockin compared to WT mice [51]; this
ﬁnding is consistent with and supports the lack of effect of the FHM1
mutation on presynaptic P/Q channels at the peripheral terminals of
CGRP-expressing (including CS) dural afferents, as demonstrated for
P/Q channels at the soma of small CS TG neurons [51]. These data
argue against the idea that the facilitation of CGRP-dependent dural va-
sodilation and CGRP-dependent dural mast cell degranulation contrib-
ute to the generation of migraine pain in FHM1 [36].
Despite the lower % of CGRP-expressing neurons recently reported in
the trigeminal ganglion of R192Q knockin compared to WT mice [137],
the FHM1mutation did increase evoked CGRP release from intact trigem-
inal ganglia [51] and both basal and evoked CGRP release from cultured
TG neurons [138] of R192Q knockin mice, suggesting alternative roles.
There is in vivo and in vitro evidence for non-synaptic intraganglionic
release of CGRP, substance P and ATP from TG neuron cell bodies in
response to depolarizing stimuli [139,140]. It has been suggested that
CGRP-mediated intraganglionic crosstalk between neurons and between
neurons and satellite glial cells could promote and maintain a neuron–
glia inﬂammatory cycle that might contribute to peripheral trigeminal
sensitization [55,57]. This suggestion is mainly based on the evidence
that prolonged application of CGRP to cultures of TG neurons and/or sat-
ellite glial cells leads to increased gene expression and/or membrane
targeting of speciﬁc receptors (e.g. P2X3) in neurons and to increased
expression of inﬂammatory genes and release of inﬂammatorymediators
from satellite glial cells; these inﬂammatory mediators can sensitize TG
neurons and act back on glial cells further activating them ([36] and
references therein). Assuming that similar phenomena occur in the tri-
geminal ganglion in vivo upon prolonged elevations of CGRP, the en-
hanced intraganglionic CGRP release measured in KI mice suggests, as a
possible working hypothesis, that FHM1 mutations might facilitate pe-
ripheral sensitization at the ganglion level. As a matter of fact, there isPC
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crosstalk following exposure to proinﬂammatory stimuli in cultured TG
neurons from juvenile R192Q knockin mice [138]. Moreover, a stronger
basal activation of macrophages, a larger basal release of TNFα and an
enhanced P2X3 receptor-mediated neuronal current (accompanied by a
smaller effect of a canonical inﬂammatory agent on these processes)
have been recently reported in cultured TG neurons from FHM1 knockin
mice [141,142]. On the basis of these ﬁndings, it has been suggested that
FHM1 mutations might lead to a basal inﬂammatory milieu within the
trigeminal ganglion [141]. Interestingly, in both cultured TG neurons
and intact ganglia a larger fraction of TG neurons was immunoreactive
for active phosphorylated CaMKII in R192Q knockin compared to WT
mice. Blockade of P/Q channels in cultured TGneurons eliminated the dif-
ference in amount of phosphoprotein between the two genotypes,
suggesting facilitation of basal CaV2.1-dependent Ca signaling [142].
The functional analysis of TG neurons and dural afferents in R192Q
knockin mice supports the conclusions that i) the FHM1 mutations
may lead to gain-of function of the P/Q Ca current in certain TG neurons
without affecting the P/Q current in other TGneuron subtypes, including
small-capsaicin-sensitive dural afferents; and ii) the FHM1 mutations
lead to several gain-of-function effects at the trigeminal ganglion level,
but do not alter the functional properties of small capsaicin-sensitive
peptidergic dural afferents, including CGRP release from their peripheral
terminals at the dura (Fig. 3).
Again, as in the case of the cortical neurophysiological processes
discussed in Section 4, different conclusions may be drawn from the re-
cent functional analysis of an FHM1 mutation in transfected neonatal TG
neurons expressing humanmutant CaV2.1α1 subunits [80]. In these neu-
rons, the P/Q current density wasmuch smaller than in neurons express-
ing the WT channel, and small CGRP-expressing IB4-negative neurons
showed a compensatory increase in low-voltage activated Ca current, a
lower rheobase and higher AP frequency, with unaltered AP duration,
compared to neurons expressing the WT channel [80]. Assuming that
this subpopulation of TG neurons innervates the dura, one could predict
enhanced CGRP release at the dura as a consequence of the enhanced
excitability indirectly producedby the FHM1mutation in transfectedneu-
rons. This prediction contrastswith the unaltered CGRP releasemeasuredCI-T
CS
Gain-of-function of CaV2.1 channels resulting in prolongation 
small CI-T trigeminal ganglion neurons, but unaltered  CaV2.1
and unaltered excitability in small capsaicin-sensitive dural af
Increased CGRP release at the trigeminal ganglion  that migh
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Fig. 3. Functional alterations in trigeminal ganglion neurons of an FHM1 knockin mou
capsaicin-sensitive (CS) trigeminal ganglion (TG) neurons that innervate the dura, and acc
of the CaV2.1 channel resulting in increased AP-evoked Ca inﬂux and prolongation of the A
(CI-T neurons, that do not innervate the dura). Increased CGRP release and phosphory
CGRP-mediated neuron to glia crosstalk after an inﬂammatory stimulus in cultured TG neur
of TNFα and stronger basal activation of macrophages, suggesting a basal inﬂammatory miat the dura of FHM1 knockin mice [51], further stressing the importance
of studying neurophysiological processes potentially involved in the path-
ogenesis of FHM1 in neurons expressing the CaV2.1 channels at the native
endogenous level.
7. Conclusions
The functional consequences of FHM1 mutations can be summarized
as follows:
i) gain-of-function of human CaV2.1 channels, mainly due to in-
creased channel open probability and channel activation at
lower voltages; the mutations also affect channel modulation
in that they reduce G-protein mediated inhibition and largely
occlude Ca-dependent facilitation of CaV2.1 channels;
ii) neuron-subtype and synapse-speciﬁc gain-of-function effects,
depending on the speciﬁc CaV2.1 splice variant and/or auxiliary
subunit and/or the action potential duration in different neurons
and/or neuronal subcellular compartments;
iii) enhanced cortical excitatory synaptic transmission at pyramidal
cell synapses, but, in striking contrast, unaltered inhibitory synap-
tic transmission at fast-spiking interneuron synapses, suggesting
dysfunctional regulation of the cortical excitatory–inhibitory
balance in FHM1;
iv) facilitation of induction and propagation of experimental CSD due
to gain-of-function of cortical glutamatergic synaptic transmis-
sion;
v) several gain-of-function effects at the trigeminal ganglion level,
but lack of effects on small capsaicin-sensitive peptidergic dural
afferents and on CGRP release at the dura, suggesting that the
facilitation of peripheral mechanisms of CGRP action at the
dura does not contribute to the generation of headache in FHM1.
As a whole, the functional consequences of FHM1 mutations
i) strengthen the view of CSD as a key migraine trigger; and ii) support
the view of migraine as a disorder of brain excitability characterized by
deﬁcient regulation of the cortical excitatory–inhibitory balance, andof the AP in 
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se model. Unaltered CaV2.1 channel gating and unaltered excitability in small-size
ordingly, unaltered depolarization-evoked CGRP release at the dura. Gain-of-function
P in small-size capsaicin-insensitive TG neurons expressing a T-type calcium current
lated CaMKII in intact trigeminal ganglia and cultured TG neurons. Facilitation of
ons, showing enhanced P2X3 receptor-mediated currents with enhanced basal release
lieu.
1663D. Pietrobon / Biochimica et Biophysica Acta 1828 (2013) 1655–1665give insights into the possible underlying molecular and cellular mech-
anisms and their relationship to CSD susceptibility.
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